Cargando…
Update on new biologics for intractable eosinophilic asthma: impact of reslizumab
A small percentage of patients with asthma have uncontrolled symptoms and frequent exacerbations, despite treatment with inhaled corticosteroids and other agents. It has become clear that different subtypes of this severe, treatment-resistant group exist due to different mechanisms of the disease. A...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5951215/ https://www.ncbi.nlm.nih.gov/pubmed/29780238 http://dx.doi.org/10.2147/DDDT.S109489 |